Evotec AG and Padlock Therapeutics have further extended their collaboration after completing an initial goal in a program focused on developing inhibitors of protein-arginine deiminases (PADs), enzymes that play an important role in autoimmune diseases.   The collaboration, signed in January 2014, now extends through March 2017. Under the alliance, Evotec provides a range of research activities including in vitro biology, high-throughput screening, structural biology, medicinal and computationa...